Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells

Molecular Cancer Therapeutics

Volumn 12, Issue 9, 2013, Pages 1783-1795

  Karpel Massler, Georg ^a   Westhoff, M Andrew ^a   Zhou, Shaoxia ^a   Nonnenmacher, Lisa ^a   Dwucet, Annika ^a   Kast, Richard E ^b   Bachem, Max G ^a   Wirtz, Christian R ^a   Debatin, Klaus Michael ^a   Halatsch, Marc Eric ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; RAC1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MICE, INBRED NOD; MOLECULAR TARGETED THERAPY; PYRIMIDINES; QUINAZOLINES; RAC1 GTP-BINDING PROTEIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884519445     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0052     Document Type: Article

References (43)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507.
3. Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoom M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
4. Karpel-Massler G, Schmidt U, Unterberg A, Halatsch M. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas - where do we stand? Mol Cancer Res 2009;7:1000-12.
5. Salomon D, Brandt R, Ciardello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
6. Lund-Johansen M, Bjerkvig R, Humphrey P, Bigner S, Bigner D, Laerum O. Effect of epidermal growth factor on glioma cellgrowth, migration, and invasion in vitro. Cancer Res 1990;50: 6039-44.
7. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-70.
8. Arteaga C. HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003;30:3-14.
9. Scagliotti G, Selvaggi G, Novello S, Hirsch F. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004;10: 4227s-32s.
10. Peereboom D, Shepard D, Ahluwalia M, Brewer C, Agarwal N, Stevens G, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 2010;98:93-9.
11. van den Bent M, Brandes A, Rampling R, Kouwenhoven M, Kros J, Carpentier A, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009;27:1268-74.
12. Karpel-Massler G, Westhoff M-A, Kast R, Wirtz C, Halatsch M-E. Erlotinib in glioblastoma: lost in translation? Anticancer Agents Med Chem 2011;11:748-55.
13. Halatsch M-E, Low S, Mursch K, Hielscher T, Schmidt U, Unterberg A, et al. Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. J Neurosurg 2009;111:211-8.
14. Didsbury J, Weber RF, Bokoch GM, Evans T, Snyderman R. Rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem 1989;264:16378-82.
15. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-35.
16. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 2004;101:7618-23.
17. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999;81:682-7.
18. Jordan P, Brazao R, Boavida MG, Gespach C, Chastre E. Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene 1999;18:6835-9.
19. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, et al. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 2000;19: 3013-20.
20. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 1995;15:6443-53.
21. Malliri A, van der Kammen RA, Clark K, van der Valk M, Michiels F, Collard JG. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 2002;417:867-71.
22. Michiels F, Habets GG, Stam JC, van der Kammen RA, Collard JG. A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature 1995;375:338-40.
23. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature 1995;374:457-9.
24. Yuan L, Santi M, Rushing EJ, Cornelison R, MacDonald TJ. ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration. Clin Exp Metastasis 2010;27:481-91.
25. Senger D, Tudan C, Guiot M-C, Mazzoni I, Molenkamp G, LeBlanc R, et al. Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. Cancer Res 2002;62:2131-40.
26. Yoon CH, Hyun KH, Kim RK, Lee H, Lim EJ, Chung HY, et al. The small GTPase Rac1 is involved in the maintenance of stemness and malignancies in glioma stem-like cells. FEBS Lett 2011;585:2331-8.
27. Jung IH, Leem GL, Jung DE, Kim MH, Kim EY, Kim SH, et al. Glioma is formed by active Akt1 alone and promoted by active Rac1 in transgenic zebrafish. Neuro Oncol 2013;15:290-304.
28. Chan AY, Coniglio SJ, Chuang YY, Michaelson D, Knaus UG, Philips MR, et al. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 2005;24:7821-9.
29. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 2008;68:6271-80.
30. Goldberg L, Kloog Y. A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 2006;66:11709-17.
31. Meijering E, Dzyubachyk O, Smal I. Methods for cell and particle tracking. Methods Enzymol 2012;504:183-200.
32. Su Y, Ray M, Lin T, Seidel N, Bodine D, Meltzer P, et al. Reversion of monochromosome-mediated suppression of tumorigenicity in malignant melanoma by retroviral transduction. Cancer Res 1996;56: 3186-91.
33. Kunzi-Rapp K, Genze F, Kufer R, Reich E, Hautmann R, Gschwend J. Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. J Urol 2001;166:1502-7.
34. Kufer R, Hofer M, Altug V, Zorn C, Genze F, Kunzi-Rapp K, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 2004;90:535-41.
35. Halatsch M-E, Gehrke E, Vougioukas V, Botefur I, Efferth T, Gebhardt E, et al. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J Neurosurg 2004;100:523-33.
36. Ramis G, Thomas-Moya E, Fernandez de Mattos S, Rodriguez J, Villalonga P. EGFR inhibition in glioma cells modulates rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth. PLoS ONE 2012;7:e38770.
37. Stommel J, Kimmelman A, Ying H, Nabioullin R, Ponugoti A, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318: 287-90.
38. Vivanco I, Robins H, Rohle D, Campos C, Grommes C, Nghiemphu P, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inibitors. Cancer Discov 2012;2: 458-71.
39. Barkovich K, Hariono S, Garske A, Zhang J, Blair J, Fan Q, et al. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov 2012;2: 450-7.
40. Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, MasonW, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 2010;65: 353-61.
41. Lassman A, Rossi M, Raizer J, Razier J, Abrey L, Lieberman F, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005; 11:7841-50.
42. Yoshida T, Zhang Y, Rivera Rosado LA, Chen J, Khan T, MoonSY, et al. Blockade of RAC1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2010;9: 1657-68.
43. Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther 2013;12:326-38.